Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04549974
Other study ID # ICM 2020-2719
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 25, 2020
Est. completion date March 31, 2023

Study information

Verified date May 2023
Source Montreal Heart Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the increase in myocardial blood flow during heat exposure and how this response is affected by age and coronary artery disease.


Description:

As a result of climate change, heat waves are more frequent and of longer duration. These heat waves are associated with a higher risk of hospitalization and mortality in vulnerable populations such as people with cardiovascular disease or cardiovascular risk factors. It has been hypothesized that this observation may be explained by the cardiovascular demands imposed by heat exposure. Heat exposure requires increased cardiac work that may place individuals with cardiovascular disease at risk of ischemic events if the metabolic demand is not compensated by adequate blood supply. However, the extent to which cardiac work increases during heat exposure remains unknown. The aim of this study is to test the hypothesis that heat exposure increases myocardial blood flow and that this increase is affected by age and coronary artery disease.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria for Healthy Participants: - Age between 18-40 years or 60-80 years - Non-smoker (=1 year) - Non-diabetic - Normal kidney function - Body Mass Index <30 kg/m2 - Resting blood pressure <140/<90 mmHg - Resting heart rate <100 bpm Inclusion Criteria for Participants with Coronary Artery Disease: - Age between 60-80 years old - History of angiographic coronary disease (=70% arterial diameter narrowing of at least one major epicardial coronary artery) and/or prior coronary revascularization and/or documented prior acute coronary syndrome and/or perfusion defect during stress testing - Stable medications (=4 weeks) prior to enrollment Exclusion Criteria for Healthy Participants: - Diagnosis of heart, vascular, respiratory, neurological or metabolic disease and/or a prescription of medication for the treatment of these diseases - Pregnancy or lactation - Dyslipidemia not controlled by medication Exclusion Criteria for Participants with Coronary Artery Disease: - Recent hospitalization (<3 months) related to coronary artery disease - Unstable angina (<3 months) - Recent coronary artery bypass surgery (<3 months) - Left branch block - Ejection fraction <40% and/or clinical signs of heart failure - Severe valvular heart disease - Hypertension not controlled by medication - Diabetes not controlled by medication and/or serious complications related to diabetes

Study Design


Intervention

Other:
Heat exposure
Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.

Locations

Country Name City State
Canada Montreal Heart Institute Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Montreal Heart Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Global myocardial blood flow Measured by PET imaging with 82rubidium Change from baseline to an increase in internal body temperature of 1.5 degrees Celsius, estimated average = 90 minutes
Secondary Myocardial blood flow distribution Measured by PET imaging with 82rubidium Change from baseline to an increase in internal body temperature of 1.5 degrees Celsius, estimated average = 90 minutes
Secondary Heart rate Measured by electrocardiogram Change from baseline to an increase in internal body temperature of 1.5 degrees Celsius, estimated average = 90 minutes
Secondary Systolic and diastolic blood pressure Measured by automated auscultation of the brachial artery Change from baseline to an increase in internal body temperature of 1.5 degrees Celsius, estimated average = 90 minutes
Secondary Body weight Measured with a scale Measured before and after heat exposure, estimated average = 120 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1